blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2364161

EP2364161 - COMPOSITIONS CONTAINING SATIOGENS AND METHODS OF USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.01.2021
Database last updated on 21.05.2024
FormerThe patent has been granted
Status updated on  07.02.2020
FormerGrant of patent is intended
Status updated on  19.09.2019
FormerExamination is in progress
Status updated on  26.07.2019
FormerGrant of patent is intended
Status updated on  17.03.2019
FormerExamination is in progress
Status updated on  12.05.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): BE		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Satiogen Pharmaceuticals, Inc.
350 10th Ave. 820
San Diego, California 92101 / US
[2011/37]
Inventor(s)01 / YOUNG, Andrew A.
P.O. Box 1169
Chapel Hill, North Carolina 27514 / US
02 / GEDULIN, Bronislava
14174 Half Moon Bay Drive
Del Mar, California 92014 / US
03 / GREENE, Howard, E.
277 Crystal Drive
Frankfort, Michigan 49635 / US
 [2011/37]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2020/11]Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Former [2013/11]Kremer, Simon Mark
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Former [2013/03]Blance, Stephen John, et al
Avidity IP
Merlin House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ / GB
Former [2012/27]Mannion, Sally Kim, et al
Avidity IP Ltd
Merlin House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ / GB
Former [2011/37]Lasterra Sánchez, Elena, et al
HLBBshaw Merlin House Falconry Court Baker's Lane
Epping, Essex CM16 5DQ / GB
Application number, filing date09829741.923.11.2009
[2020/11]
WO2009US65587
Priority number, dateUS20080118324P26.11.2008         Original published format: US 118324 P
US20090255211P27.10.2009         Original published format: US 255211 P
[2011/37]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010062863
Date:03.06.2010
Language:EN
[2010/22]
Type: A2 Application without search report 
No.:EP2364161
Date:14.09.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 03.06.2010 takes the place of the publication of the European patent application.
[2011/37]
Type: B1 Patent specification 
No.:EP2364161
Date:11.03.2020
Language:EN
[2020/11]
Search report(s)International search report - published on:KR23.09.2010
(Supplementary) European search report - dispatched on:EP28.11.2012
ClassificationIPC:A61K38/16, A61P3/10, A61P3/04, A61P3/00, A61K31/56, A61K31/575
[2012/52]
CPC:
A61K31/4985 (EP,US); A61K31/575 (EP,GB,US); A61K35/413 (EP,US);
A61K45/06 (EP,US); A61K47/32 (GB); A61K47/38 (GB);
A61K9/0031 (EP,US); A61K9/02 (US); A61K9/06 (US);
A61K9/08 (US); A61K9/122 (US); A61K9/2054 (EP,US);
A61K9/284 (US); A61K9/2866 (EP,US); A61P3/00 (EP);
A61P3/04 (EP); A61P3/10 (EP); A61P43/00 (EP) (-)
C-Set:
A61K35/413, A61K2300/00 (EP,US)
Former IPC [2011/37]A61K38/16, A61P3/10, A61P3/04, A61P3/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2020/11]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN MIT SATIOGENEN UND ANWENDUNGSVERFAHREN[2011/37]
English:COMPOSITIONS CONTAINING SATIOGENS AND METHODS OF USE[2011/37]
French:COMPOSITIONS CONTENANT DES SATIOGÈNES ET LEURS PROCÉDÉS D'UTILISATION[2011/37]
Entry into regional phase01.06.2011National basic fee paid 
01.06.2011Search fee paid 
01.06.2011Designation fee(s) paid 
01.06.2011Examination fee paid 
Examination procedure01.06.2011Examination requested  [2011/37]
27.06.2013Amendment by applicant (claims and/or description)
23.10.2013Despatch of a communication from the examining division (Time limit: M06)
11.04.2014Reply to a communication from the examining division
10.10.2014Despatch of a communication from the examining division (Time limit: M02)
19.12.2014Reply to a communication from the examining division
26.06.2015Despatch of a communication from the examining division (Time limit: M06)
31.12.2015Reply to a communication from the examining division
28.04.2016Despatch of a communication from the examining division (Time limit: M04)
05.09.2016Reply to a communication from the examining division
04.05.2017Despatch of a communication from the examining division (Time limit: M06)
13.11.2017Reply to a communication from the examining division
18.03.2019Communication of intention to grant the patent
23.07.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.09.2019Communication of intention to grant the patent
29.01.2020Fee for grant paid
29.01.2020Fee for publishing/printing paid
29.01.2020Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.10.2013
Opposition(s)14.12.2020No opposition filed within time limit [2021/07]
Fees paidRenewal fee
23.11.2011Renewal fee patent year 03
26.11.2012Renewal fee patent year 04
18.11.2013Renewal fee patent year 05
10.11.2014Renewal fee patent year 06
30.11.2015Renewal fee patent year 07
28.11.2016Renewal fee patent year 08
27.11.2017Renewal fee patent year 09
27.11.2018Renewal fee patent year 10
27.11.2019Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.11.2009
AT11.03.2020
CY11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
MK11.03.2020
MT11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
PT05.08.2020
GB23.11.2020
IE23.11.2020
LU23.11.2020
BE30.11.2020
CH30.11.2020
LI30.11.2020
[2022/33]
Former [2022/32]HU23.11.2009
AT11.03.2020
CY11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
MK11.03.2020
MT11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
PT05.08.2020
GB23.11.2020
IE23.11.2020
LU23.11.2020
CH30.11.2020
LI30.11.2020
Former [2022/27]HU23.11.2009
AT11.03.2020
CY11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
MT11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
PT05.08.2020
GB23.11.2020
IE23.11.2020
LU23.11.2020
CH30.11.2020
LI30.11.2020
Former [2022/26]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
TR11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
PT05.08.2020
GB23.11.2020
IE23.11.2020
LU23.11.2020
CH30.11.2020
LI30.11.2020
Former [2022/10]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
PT05.08.2020
GB23.11.2020
IE23.11.2020
LU23.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/49]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
GB23.11.2020
IE23.11.2020
LU23.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/46]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
IE23.11.2020
LU23.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/37]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU23.11.2020
CH30.11.2020
LI30.11.2020
Former [2021/33]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
LU23.11.2020
Former [2021/31]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
MC11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2021/10]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
PL11.03.2020
RO11.03.2020
SE11.03.2020
SI11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2021/09]AT11.03.2020
CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
IT11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2021/08]CZ11.03.2020
DK11.03.2020
EE11.03.2020
ES11.03.2020
FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/50]CZ11.03.2020
EE11.03.2020
FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/49]CZ11.03.2020
FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
SE11.03.2020
SK11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/48]FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
RO11.03.2020
SE11.03.2020
SM11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
PT05.08.2020
Former [2020/47]FI11.03.2020
HR11.03.2020
LT11.03.2020
LV11.03.2020
NL11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
Former [2020/46]FI11.03.2020
HR11.03.2020
LV11.03.2020
NL11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
IS11.07.2020
Former [2020/45]FI11.03.2020
HR11.03.2020
LV11.03.2020
NL11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
Former [2020/39]FI11.03.2020
HR11.03.2020
LV11.03.2020
SE11.03.2020
BG11.06.2020
NO11.06.2020
GR12.06.2020
Former [2020/38]FI11.03.2020
HR11.03.2020
LV11.03.2020
SE11.03.2020
NO11.06.2020
GR12.06.2020
Former [2020/37]FI11.03.2020
HR11.03.2020
LV11.03.2020
SE11.03.2020
NO11.06.2020
Former [2020/35]FI11.03.2020
NO11.06.2020
Documents cited:Search[XY]WO2006116814  (VANADIS BIOSCIENCE LTD [NZ], et al) [X] 1-12,14,15 * paragraph [0023] * * paragraph [0058] * * paragraph [0068] * * claims 1-19 * [Y] 13;
 [E]WO2011038014  (BIOKIER INC [US], et al) [E] 1-15 * paragraph [0013] * * paragraph [0049] * * claims 1-21 *;
 [E]WO2010081079  (BIOKIER INC [US], et al) [E] 1-10,12-15 * paragraph [0012] * * claims 1-13 *;
 [Y]US2008145453  (LOPEZ ROMAN [FR], et al) [Y] 13 * paragraph [0047] *;
 [Y]JP2005097216  (KANEKA CORP) [Y] 13 * abstract *
 [XYI]  - HOSNY EHAB A ET AL, "Evaluation of efficiency of insulin suppository formulations containing sodium salicylate or sodium cholate in insulin dependent diabetic patients", BOLLETTINO CHIMICO FARMACEUTICO, SOCIETA EDITORIALE FARMACEUTICA, MILANO, IT, (20030101), vol. 142, no. 8, ISSN 0006-6648, pages 361 - 366, XP009164921 [X] 1,2,4-8,12,14,15 * the whole document * [Y] 13 [I] 3,9-11,13
 [XYI]  - HOSNY E A ET AL, "Effect of different bile salts on the relative hypoglycemia of witepsol W35 suppositories containing insulin in diabetic Beagle dogs.", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY SEP 2001, (200109), vol. 27, no. 8, ISSN 0363-9045, pages 837 - 845, XP009164902 [X] 1,2,4-8,12,14,15 * the whole document * [Y] 13 [I] 3,9-11,13

DOI:   http://dx.doi.org/10.1081/DDC-100107248
 [Y]  - YAMAMOTO A ET AL, "Colon -specific delivery of peptide drugs and anti-inflammatory drugs using chitosan capsules", SCIENCES TECHNIQUES ET PRATIQUES STP PHARMA SCIENCES, PARIS, FR, (20000101), vol. 10, no. 1, ISSN 1157-1489, pages 23 - 34, XP009164920 [Y] 13 * the whole document *
 [XYI]  - EL-SHATTAWY H ET AL, "EFFECTIVENESS OF RECTAL INSULIN SUPPOSITORIES CONTAINING SODIUM CHOLATE IN NORMAL AND INSULIN DEPENDENT DIABETIC SUBJECTS", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, (19910101), vol. 8, no. 10, Suppl, ISSN 0724-8741, page S157, XP009164929 [X] 1,2,4-8,12,14,15 * the whole document * [Y] 13 [I] 3,9-11,13
 [XYI]  - HOSNY ET AL, "Relative hypoglycemia of rectal insulin suppositories containing deoxycholic acid, sodium taurocholate, polycarbophil, and their combinations in diabetic rabbits", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, (19990101), vol. 25, no. 6, ISSN 0363-9045, pages 745 - 752, XP009164926 [X] 1,2,4-8,12,14,15 * the whole document * [Y] 13 [I] 3,9-11,13

DOI:   http://dx.doi.org/10.1081/DDC-100102234
 [IY]  - TOZAKI H ET AL, "CHITOSAN CAPSULES FOR COLON-SPECIFIC DRUG DELIVERY: IMPROVEMENT OF INSULIN ABSORPTION FROM THE RAT COLON", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (19970901), vol. 86, no. 9, doi:10.1021/JS970018G, ISSN 0022-3549, pages 1016 - 1021, XP000696914 [I] 1-15 * the whole document * [Y] 13

DOI:   http://dx.doi.org/10.1021/js970018g
International search[Y]US2003219472  (PAULETTI GIOVANNI M [US], et al);
 [A]US6309663  (PATEL MAHESH V [US], et al)
 [Y]  - KATSUMA S ET AL., "Bile acids promote glucagon-like peptide-1 secretion thro ugh TGR5 in a murine enteroendocrine cell line STC-1", BIOCHEM BIOPHYS RES CO MMUN., (200504), vol. 329, no. 1, pages 386 - 390, XP004757042

DOI:   http://dx.doi.org/10.1016/j.bbrc.2005.01.139
 [Y]  - ONAGA T ET AL., "Multiple regulation of peptide YY secretion in the digestiv e tract", PEPTIDES, (200202), vol. 17, no. 5, pages 279 - 290, XP008140745
Examination   - MARTINEZ JESSE D ET AL, "Different bile acids exhibit distinct biological effects: The tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation", NUTRITION AND CANCER,, (19980101), vol. 31, no. 2, ISSN 0163-5581, pages 111 - 118, XP009184929

DOI:   http://dx.doi.org/10.1080/01635589809514689
by applicantWO2006116814
 WO2011038014
 WO2010081079
 US2008145453
 JP2005097216
 US2003219472
 US6309663
 WO2008091540
 WO2008067219
 US2008221161
    - HOSNY EHAB A et al., Bollettino Chimico Farmaceutico, Societa Editoriale Farmaceutica, (20030101), vol. 142, pages 361 - 366
    - HOSNY EHAB A et al., Drug Development and Industrial Pharmacy, (20010900), vol. 27, no. 8, pages 837 - 845
    - YAMAMOTO A et al., Sciences Techniques et Pratiques STP Pharma Sciences, (20000101), vol. 10, no. 1, pages 23 - 34
    - EL-SHATTAWY H et al., Pharmaceutical Research, Kluwer Academic Publishers, (19910101), vol. 8, page 157
    - HOSNY et al., Drug Development and Industrial Pharmacy, (19990101), vol. 25, no. 6, pages 745 - 752
    - TOZAKI H et al., Journal of Pharmaceutical Sciences, American Pharmaceutical Association, (19970901), vol. 86, pages 1016 - 1021
    - KATSUMA S et al., Biochem Biophys Res Commun., (20050400), vol. 329, no. 1, pages 386 - 390
    - ONAGA T et al., Peptides, (20020200), vol. 17, no. 5, pages 279 - 290
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.